Stephan P. Babirak, MD, PhD

Experts explore why FCS remains one of the most emotionally and clinically challenging lipid disorders despite decades of management effort.

Clinical Burden and Unmet Need in Familial Chylomicronemia Syndrome

For lipidologists who manage patients with familial chylomicronemia syndrome (FCS), the disease carries a weight that extends well beyond laboratory values. Patients are known by name, their emergency room admissions are anticipated, and despite decades of effort, the tools available to prevent recurrent pancreatitis have historically fallen short.

Alan Brown, MD, MHA, opens by capturing what separates FCS from most lipid disorders: physicians know these patients intimately, because despite fibrates, omega-3 fatty acids, and every available intervention, patients return month after month in crisis. The relationship between physician and patient often deteriorates under the weight of repeated hospitalizations and failed treatment.

Stephan P. Babirak, MD, PhD, echoes that characterization, describing FCS as the most difficult lipid disorder to treat. First described in the medical literature in 1932, the disease has proved largely resistant to pharmacotherapy and only partially responsive to dietary intervention, while inflicting morbidity and mortality that can permanently alter a patient's life. Babirak notes that the diagnosis can be suspected from the appearance of a blood draw alone, which takes on a creamy or tomato-soup consistency in patients with severe chylomicronemia.

Both experts describe the longitudinal relationship with FCS patients as distinct from almost any other in lipid medicine. Babirak recounts a patient who left his practice for 8 years out of frustration, only to be recontacted once new therapeutic options became available. Brown describes the cycle of waiting for the emergency room call, and the frustration that arises when physicians unfamiliar with the syndrome attribute the presentation to poor adherence or alcohol use. These dynamics, both experts note, are central to the clinical challenge of FCS management.

Stephan P. Babirak, MD, PhD

Articles